Ahencio, Belen A.
HRN: 26-18-84 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
11/17/2024
CLINDAMYCIN 300MG (CAP)
11/17/2024
11/23/2024
PO
300
TID
S/P Wound Debridement, Cellulitis
Waiting Final Action
Indication: Empiric Type of Infection: Skin & Soft Tissue Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes